199 related articles for article (PubMed ID: 18282451)
1. [Long term effects of raloxifen on the bones].
Eiken PA
Ugeskr Laeger; 2008 Jan; 170(4):224-6. PubMed ID: 18282451
[TBL] [Abstract][Full Text] [Related]
2. [Effects of SERMs on bone health. Combination therapy with raloxifene].
Gorai I; Hori H
Clin Calcium; 2010 Mar; 20(3):408-12. PubMed ID: 20190371
[TBL] [Abstract][Full Text] [Related]
3. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
[No Abstract] [Full Text] [Related]
4. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
5. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
[TBL] [Abstract][Full Text] [Related]
6. FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis.
Howard E; Tagliarino-Jones H
Am Fam Physician; 2010 Feb; 81(4):439. PubMed ID: 20148496
[No Abstract] [Full Text] [Related]
7. [Treating with what? Therapy for how long?].
MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
[No Abstract] [Full Text] [Related]
8. [Treatment of osteoporosis with PTH].
Takeuchi Y
Clin Calcium; 2014 Jun; 24(6):893-902. PubMed ID: 24870841
[TBL] [Abstract][Full Text] [Related]
9. [An advantage for compliance: alendronate once weekly].
MMW Fortschr Med; 2005 Dec; 147(49-50):75. PubMed ID: 16401017
[No Abstract] [Full Text] [Related]
10. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
11. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
Rosa J; Vanuga P; Payer J; Svobodník A
Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
[TBL] [Abstract][Full Text] [Related]
12. A rational approach to evidence gaps in the management of osteoporosis.
Rosen CJ; Brown SA
Am J Med; 2005 Nov; 118(11):1183-9. PubMed ID: 16271898
[TBL] [Abstract][Full Text] [Related]
13. [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].
Dimai HP; Pietschmann P; Resch H; Preisinger E; Fahrleitner-Pammer A; Dobnig H; Klaushofer K;
Wien Med Wochenschr Suppl; 2009; (122):1-34. PubMed ID: 19484202
[TBL] [Abstract][Full Text] [Related]
14. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
Yamaguchi T; Sugimoto T
Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
[TBL] [Abstract][Full Text] [Related]
15. Atypical fractures on long term bisphosphonates therapy.
Hussein W; Cunningham C; Logan H; Fallon C; Murphy S
Ir Med J; 2011; 104(10):308, 310. PubMed ID: 22256444
[TBL] [Abstract][Full Text] [Related]
16. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
Anić B; Grazio S
Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557
[TBL] [Abstract][Full Text] [Related]
17. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
Ohta H
Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
[TBL] [Abstract][Full Text] [Related]
18. [Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis].
Matsuo K; Fujinaga M; Tsuchiya K; Nakamoto M; Yasunaga C
Clin Calcium; 2005 Sep; 15 Suppl 1():92-6; discussion 96-7. PubMed ID: 16272639
[TBL] [Abstract][Full Text] [Related]
19. Do not use bisphosphonate therapy indefinitely for fracture prevention.
Prescrire Int; 2008 Oct; 17(97):214. PubMed ID: 19536944
[TBL] [Abstract][Full Text] [Related]
20. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
Soen S
Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]